Mounjaro crosses Rs 50 cr in India in 90 days as Wegovy joins fray
tirzepatide
),
Eli Lilly
's blockbuster weight-loss and diabetes drug, jumped nearly nine times since its launch in March to ₹26 crore in June, a month that also saw the launch of
Wegovy
from competitor
Novo Nordisk
. In the last one month itself, Mounjaro sale doubled from ₹13 crore in May, according to data from
PharmaTrac
. So far the total sales value of Mounjaro is ₹50 crore in India.
In volume terms, the numbers over seven times since March to 88,000 units sold in June. In the last two months, the quantity of Mounjaro sold has grown threefold from 28,000 units in April, the data showed. On the other hand, a week within its launch, Wegovy that is available in self-injectable pen-filled version, recorded a sale of ₹2.53 crore, shows the data.
Doctors said the increased awareness as well as social media conversations and publicity about both the molecules is prompting many young adults in their thirties and early forties showing interest.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
13 hours ago
- Time of India
Indians increasingly aware of weight loss drugs, but most wary their adoption: Survey
New Delhi: While the awareness of weight loss drugs in India is burgeoning at an unprecedented pace following the high-profile launches by global giants, most of the citizens in the country have reported to prefer non-medical options considering their side effects. According to a recent survey conducted by Morning Consult on behalf of the Physicians Committee for Responsible Medicine over 1000 individuals, 87 per cent of the respondents believe "it is important to learn about non-drug-supported weight loss methods following concerns over safety and long-term use." As per the survey findings, 82 per cent of respondents had heard of these drugs, however, only 18 per cent could correctly explain how these drugs work and 65 per cent voiced that their benefits are highly exaggerated. Commenting on the survey findings Dr Vanita Rahman, internal medicine physician with the Physicians Committee said that many people are concerned about side effects and safety and are asking what options exist beyond medications. As a better alternative, the medical experts suggest focusing on lifestyle changes such as a low fat based diet to sustain long term benefits. 'A plant-based diet—low in fat and rich in fiber—can support long-term weight control without the risks associated with drug therapies. It's a sustainable strategy that equips patients with safer, evidence-based options for weight control,' said Dr Rahman. Adding to it Dr Zeeshan Ali, a nutrition researcher with the Physicians Committee extended that a Plant-based diet reduces the risk of obesity among adults who are genetically predisposed to the disease, and can help people reach a healthier Body Mass Index (BMI). Citing a study which analyzed the findings of the last National Family Health Survey the committee noted that overweight and obesity tend to affect Indian families as a unit, not just individuals and should prioritize household-level interventions, over purely individual approaches. In March this year, US giant Eli Lilly launched its blockbuster drug Mounjaro (tirzepatide) in India while its arch-rival Danish drug maker Novo Nordisk followed suit with the launch of its alternative brand Wegovy (semaglutide) last month. According to PharmaTrack data, as of June 2025 Lilly has sold around 88,000 identical units of Mounjaro (including both 2.5 mg and 5mg vial) while Novo has sold close to 17,000 units since its launch in June this year. Of India's total ₹628 crore anti-obesity drug market, semaglutide accounts for 66 per cent of the total market with a moving annual turnover (MAT) of ₹412 crore while tirzepatide with a MAT of ₹50 crore owns 8 per cent of the total share.
NDTV
15 hours ago
- NDTV
Wegovy And Mounjaro For Weight Loss Are In, But India Wants A No-Drug Obesity Fix
Obesity is becoming an increasingly serious concern in India. According to several studies, India now ranks third globally in the number of obese individuals, with a growing proportion of both adults and children affected. With the launch of weight-loss drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) in India (medications that have made international headlines) many hoped these pharmaceutical solutions might help address the country's escalating obesity crisis. However, a new nationwide survey reveals a strong preference among Indians for non-drug approaches. An overwhelming 87% of Indian adults say it is important to learn about weight-loss methods that do not rely on medication, citing concerns about the safety and long-term effects of such treatments. "As conversations around weight-loss drugs dominate headlines, many people are concerned about side effects and safety, and are asking what options exist beyond medication," says Dr Vanita Rahman, Internal Medicine Physician with the Physicians Committee for Responsible Medicine. According to Dr Rahman, adopting a healthful, plant-based diet - low in fat and high in fibre - can promote sustainable weight loss without the risks posed by drug therapies. "It's a long-term strategy that equips patients with safer, evidence-based options for weight control," she said. What The Survey Found The survey, conducted by Morning Consult on behalf of the Physicians Committee, also highlighted a widespread lack of understanding about the much-publicised GLP-1 weight-loss medications. The nationally representative survey included responses from over 1,000 Indian adults across age groups, gender, regions, educational backgrounds and rural-urban divides, in alignment with the latest Indian census data. The study found that while 82% of respondents had heard of these drugs, only 18% could accurately explain how they work. Many mistakenly believed that the drugs burn fat (26%) or boost metabolism (20%), while another 18% admitted they were unsure. Concerns around safety and effectiveness were also prevalent, according to the survey: 75% had heard about side effects during usage 69% were aware of risks after discontinuation 65% believed the media exaggerates the benefits 60% felt drug-based solutions receive excessive media attention These medication can cause nausea, vomiting and constipation. More serious, long-term side effects may include increased risks of gall-bladder disease, pancreatitis, thyroid cancer, eye conditions, and harm to a developing foetus. Research further shows that 88% of users do not achieve a normal body mass index (BMI) and remain overweight or obese. Nearly two out of three users stop taking the drugs within the first year, often due to side effects, high costs, or lack of effectiveness. Discontinuing the medication typically leads to rapid weight regain. Back To Basics Experts suggest that Indians are not interested in taking drugs for weight loss, instead they are truning back to traditional ways of losing weight. This also comes with the lack of awareness about weight loss drugs. "There's growing interest in approaches that are rooted in science, safe for families, and offer long-term results," says Dr Zeeshan Ali, PhD, Nutrition Researcher with the Physicians Committee. "Plant-based diets can reduce the risk of obesity even in those with a genetic predisposition and help people reach a healthier BMI," he adds. The survey findings arrive at a crucial time, following a recent study by the ICMR-National Institute for Cancer Prevention and Research (NICPR). The study, based on data from the National Family Health Survey 5, found that overweight and obesity in India often affect entire families, not just individuals. It emphasised the need for household-level interventions over purely individual strategies. "A shift towards plant-based meals could be the kind of shared dietary change that helps families improve their health together," says Dr Rahman. The results underscore the urgent need for public health campaigns that educate and empower Indians with safe, culturally relevant, and sustainable dietary solutions.
Indian Express
15 hours ago
- Indian Express
Alphabet-owned company to begin human trials for cancer drug developed using AI
Pharmaceutical firm Isomorphic Labs is set to initiate human clinical trials for its oncology drugs created using AlphaFold 3, an AI tool developed by the company in collaboration with Google DeepMind. Founded in 2021, Isomorphic Labs is a subsidiary of Google parent Alphabet. It is currently preparing to dose the first patients with the AI-engineered drug in clinical trials and is 'staffing up' ahead of the trials, Isomorphic Labs president Colin Murdoch said in a recent interview with Fortune. AlphaFold 3 is an AI tool that has been designed to help clinicians predict complex protein structures and molecular interactions. Using the tool, Isomorphic Labs were able to take major strides in terms of development of the drug. Oncology drugs are essential medications as they play a vital role in the treatment of cancer. The drug either kills the cancer cells or slows their growth, allowing for further treatment. According to the World Health Organization (WHO), there were around 20 million new cancer cases and 9.7 million cancer-related deaths recorded in 2022. However, AI tools such as AlphaFold 3 are said to have vast potential in helping discover new types of drugs for treating terminal illnesses like cancer. In March last year, Isomorphic Labs was able to raise over 600 million dollars through a funding round led by Thrive Capital. The company confirmed the use of this funding for the development of the AI drug-design engine, and helping toward their push to clinical trials. 'This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programmes into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI,' Demis Hassabis, the CEO of both Isomorphic Labs and Google DeepMind, said. The company has inked partnerships worth over three billion dollars with pharma giants such as Novartis and Eli Lilly. The company's goal is to build a 'world-class drug design engine' that merges AI and human expertise to engineer new medications with a higher success rate at a cheaper cost for both manufacturers and consumers. With the rapid rise of AI, other biotech companies such as Anima Biotech, Iktos, and Novo Nordisk are also harnessing the technology for more effective operations. Notably, Novo Nordisk signed a deal worth 2.76 billion dollars with Valo Health, aiming to make use of AI in their drug discovery process. As per GlobalData statistics, over 3,000 drugs exist that have either been developed or re-purposed using AI technologies. While most of them are in the early stages of their development, they are still to be clinically tested on humans. With its upcoming human tests, Isomorphic Labs could potentially pave the way for further progress in the biotech application of AI.
